Subclinical cardiac involvement: A subtle foe in the setting of systemic sarcoidosis

Subclinical cardiac involvement: A subtle foe in the setting of systemic sarcoidosis

Authors

  • Kenan Yalta Trakya University, Cardiology Department, Edirne, Turkey
  • Ugur Ozkan Trakya University, Cardiology Department, Edirne, Turkey
  • Irem B Bulburu Trakya University, Cardiology Department, Edirne, Turkey
  • Muhammet Gurdogan Trakya University, Cardiology Department, Edirne, Turkey
  • Ertan Yetkın Şişli Kolan Hospital, Cardiology Department, Istanbul, Turkey

Keywords:

subclinical cardiac sarcoidosis, implications, clinical patterns, muscular involvement

Abstract

.

References

1. Uslu Biner I, Aslan S, Ak Sivrikoz I, Seker NS. A unique case of extrapulmonary sarcoidosis on F18 FDG PET/CT: “tiger man”. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17033.

2. Quaggetto M, Ben Salem T, Haroche J, et al. Janus kinase inhibitors in pulmonary and extrapulmonary sarcoidosis: a case series and a systematic review of the literature. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17246.

3. MacDowell S, Singha A, Crouser E. What’s the connection? Sarcoidosis and combined variable immunodeficiency: a single center retrospective case series. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17211.

4. Mondini L, Barbieri M, Trotta L, et al. Exploring sarcoidosis via nailfold capillaroscopy: a window into the disease’s microvascular landscape. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17137.

5. Jin L, Pan C, Sun Y, et al. Bioinformatics analysis identifies candidate biomarkers associated with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17074.

6. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–21.

7. Yalta K, Gurdogan M. Management of high-degree atrioventricular block in the setting of cardiac sarcoidosis: a therapeutic controversy. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(4):e2022036.

8. Yalta K, Yetkın E. Cardiac sarcoidosis: indications for implantable cardioverter-defibrillator therapy. CJC Open. 2022;4(9):823–4.

9. Ozyilmaz E, Akilli R, Berk İ, et al. The frequency of diastolic dysfunction in patients with sarcoidosis and its relationship with HLA DRB1* alleles. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(4):285–93.

10. Joyce E, Ninaber MK, Katsanos S, et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail. 2015;17(1):51–62.

11. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–23.

12. Yalta K, Yetkın E. Atrioventricular block in the setting of cardiac sarcoidosis: further implications. Heart Vessels. 2023;38(5):753–4.

Downloads

Published

27-03-2026

Issue

Section

Letter to Editor

How to Cite

1.
Yalta K, Ozkan U, Bulburu IB, Gurdogan M, Yetkın E. Subclinical cardiac involvement: A subtle foe in the setting of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2026 Mar. 27 [cited 2026 Apr. 17];43(1):18297. Available from: https://mail.mattioli1885journals.com/index.php/sarcoidosis/article/view/18297